A detailed history of Abingworth LLP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Abingworth LLP holds 1,435,106 shares of PHAT stock, worth $27.2 Million. This represents 5.34% of its overall portfolio holdings.

Number of Shares
1,435,106
Previous 1,435,106 -0.0%
Holding current value
$27.2 Million
Previous $15.9 Million 1.26%
% of portfolio
5.34%
Previous 5.44%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

BUY
$11.55 - $20.06 $2.68 Million - $4.65 Million
231,971 Added 19.28%
1,435,106 $19.5 Million
Q4 2019

Feb 14, 2020

BUY
$18.59 - $37.67 $22.4 Million - $45.3 Million
1,203,135 New
1,203,135 $37.4 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $742M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.